Prime Medicine, Common Etf Performance
| PRME Etf | USD 3.47 0.03 0.87% |
The etf holds a Beta of 2.24, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Prime Medicine, will likely underperform.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Prime Medicine, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Etf's primary indicators remain rather sound which may send shares a bit higher in January 2026. The latest tumult may also be a sign of longer-term up-swing for the fund shareholders. ...more
1 | Institutional investors in Prime Medicine, Inc. see US174m decrease in market cap last week, although long-term gains have benefitted them. | 10/31/2025 |
2 | Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer | 11/03/2025 |
3 | CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates | 11/07/2025 |
4 | Prime Medicine to Present at Jefferies Global Healthcare Conference | 11/11/2025 |
5 | Inhibikase Therapeutics versus Prime Medicine Financial Review | 11/14/2025 |
6 | Financial Contrast Liminatus Pharma vs. Prime Medicine | 11/20/2025 |
7 | Prime Medicine to Present at 8th Annual Evercore Healthcare Conference | 11/25/2025 |
8 | Prime Medicine, Inc. Receives Consensus Rating of Moderate Buy from Brokerages | 12/03/2025 |
9 | Prime Medicines Market Cap Up US161m Following Year Of Insider Stock Buying | 12/09/2025 |
10 | Brokerages Set Prime Medicine, Inc. Target Price at 7.45 | 12/24/2025 |
| Begin Period Cash Flow | 55.1 M | |
| Total Cashflows From Investing Activities | 68.5 M | |
| Free Cash Flow | -130.2 M |
Prime Medicine, Relative Risk vs. Return Landscape
If you would invest 667.00 in Prime Medicine, Common on October 2, 2025 and sell it today you would lose (320.00) from holding Prime Medicine, Common or give up 47.98% of portfolio value over 90 days. Prime Medicine, Common is currently does not generate positive expected returns and assumes 6.1618% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of etfs are less volatile than Prime, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Prime Medicine, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Prime Medicine,'s investment risk. Standard deviation is the most common way to measure market volatility of etfs, such as Prime Medicine, Common, and traders can use it to determine the average amount a Prime Medicine,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1377
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PRME |
Based on monthly moving average Prime Medicine, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Prime Medicine, by adding Prime Medicine, to a well-diversified portfolio.
Prime Medicine, Fundamentals Growth
Prime Etf prices reflect investors' perceptions of the future prospects and financial health of Prime Medicine,, and Prime Medicine, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Prime Etf performance.
| Return On Equity | -1.12 | ||||
| Return On Asset | -0.36 | ||||
| Operating Margin | (44.06) % | ||||
| Current Valuation | 525.8 M | ||||
| Shares Outstanding | 180.51 M | ||||
| Price To Earning | 14.40 X | ||||
| Price To Book | 3.76 X | ||||
| Price To Sales | 103.89 X | ||||
| Revenue | 2.98 M | ||||
| EBITDA | (196.34 M) | ||||
| Cash And Equivalents | 146.66 M | ||||
| Cash Per Share | 6.39 X | ||||
| Total Debt | 40.79 M | ||||
| Debt To Equity | 0.18 % | ||||
| Book Value Per Share | 0.92 X | ||||
| Cash Flow From Operations | (122.86 M) | ||||
| Earnings Per Share | (1.42) X | ||||
| Total Asset | 297.51 M | ||||
| Retained Earnings | (687.21 M) | ||||
About Prime Medicine, Performance
By analyzing Prime Medicine,'s fundamental ratios, stakeholders can gain valuable insights into Prime Medicine,'s financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Prime Medicine, has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Prime Medicine, has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. Prime Medicine is listed under Biotechnology in the United States and is traded on NASDAQ Exchange exchange.| Prime Medicine, generated a negative expected return over the last 90 days | |
| Prime Medicine, has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 2.98 M. Net Loss for the year was (195.88 M) with loss before overhead, payroll, taxes, and interest of (154.05 M). | |
| Prime Medicine, Common currently holds about 146.66 M in cash with (122.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.39, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 61.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Brokerages Set Prime Medicine, Inc. Target Price at 7.45 | |
| The fund maintains 99.55% of its assets in stocks |
Other Information on Investing in Prime Etf
Prime Medicine, financial ratios help investors to determine whether Prime Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prime with respect to the benefits of owning Prime Medicine, security.